A carregar...
Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets
The treatment options in multiple myeloma (MM) has changed dramatically over the past decade with the development of novel agents such as proteasome inhibitors (PIs); bortezomib and immunomodulatory drugs (IMiDs); thalidomide, and lenalidomide which revealed high efficacy and improvement of overall...
Na minha lista:
| Publicado no: | J Oncol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Hindawi
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6875016/ https://ncbi.nlm.nih.gov/pubmed/31781214 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/6084012 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|